The US financial year is a calendar year.
In my line of work, any US business we deal with is desperate to book all budgeted work before December 31, hence probably why revenues get a boost in the December quarter.
The chart is range bound at the moment with some volume capping the low/high limits.
With Xenos's Kojent partner selling a large chunk I doubt they will want a large spike so soon after a large block sale.
Management have stated CY21 revenues of $59M-$60M, which suggests $19M for December. Anything above $20M will be a bonus.
Payments to supplier and employees was $19.1M for September, $17.5M in June and $18.2M in March.
If $20M revenue can be the baseline in 2022, then they have passed a significant hump.
The US financial year is a calendar year. In my line of work,...
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.050(15.6%) |
Mkt cap ! $203.6M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 37.5¢ | 35.5¢ | $1.016M | 2.794M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 108230 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 72977 | 2 |
View Market Depth
| Last trade - 13.31pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
37.0¢ |
Change
0.050 ( 15.6 %) |
||||
| Open | High | Low | Volume | ||
| 35.0¢ | 37.5¢ | 35.0¢ | 890536 | ||
| Last updated 13.46pm 22/05/2024 ? | |||||
| MDR (ASX) Chart |